Semaglutide
Prescription medication — not a dietary supplement
This is an FDA-approved (or investigational) drug, not a supplement. It requires a prescription and medical supervision. The information below summarizes clinical-trial evidence for education only — it is not a recommendation to obtain or use it without a doctor.
At a glance
- Best for
- Adults with type 2 diabetes and/or obesity (and overweight with cardiovascular risk) under a prescriber
- Typical dose
- Injectable: titrated to 1-2 mg weekly for diabetes, up to 2.4 mg weekly for weight management; oral: 7-14 mg daily
- Time to effect
- Glucose lowering within weeks; substantial weight loss over months (peak around 60-68 weeks)
- Main caution
- Boxed warning for thyroid C-cell tumors (rodent medullary thyroid carcinoma); risk of pancreatitis
What is it
Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist that enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite. It is available as a once-weekly subcutaneous injection (Ozempic, Wegovy) and a once-daily oral tablet (Rybelsus). It is FDA-approved for type 2 diabetes, for chronic weight management, and to reduce cardiovascular events in specific populations.
Is it worth it for you?
Worth considering if…
- You have type 2 diabetes needing better glycemic control, prescribed and titrated by a clinician
- You have obesity (BMI >=30) or overweight (BMI >=27) with a weight-related comorbidity and are using it with diet and activity
- You have established cardiovascular disease where an agent with proven event reduction is appropriate
Probably skip if…
- You have a personal or family history of medullary thyroid carcinoma or MEN 2
- You have a history of pancreatitis or are unwilling to tolerate dose titration for GI effects
- You are pregnant or seeking rapid cosmetic weight loss without medical oversight
Evidence at a glance
| Goal | Evidence | Effect | Best fit | Time |
|---|---|---|---|---|
| type 2 diabetes glycemic control | Strong Evidence | HbA1c reduction of roughly 1.0-1.8% versus placebo or active comparators | Adults with type 2 diabetes inadequately controlled on diet or other agents | Weeks |
| chronic weight management in obesity | Strong Evidence | About 15% mean body-weight reduction versus ~2.4% with placebo at 68 weeks (STEP 1) | Adults with obesity or overweight with a weight-related condition, without diabetes | Months (continues to ~60-68 weeks) |
| cardiovascular event reduction | Strong Evidence | About 20% relative reduction in major adverse cardiovascular events versus placebo (SELECT, in overweight/obesity without diabetes) | Adults with established cardiovascular disease, with or without diabetes | Months to years |
Evidence for 3 uses
AI-assisted evidence assessment — talk to your doctor before relying on any single supplement.
type 2 diabetes glycemic control
Biomarker supportThe phase-3 SUSTAIN program randomized thousands of adults with type 2 diabetes and showed semaglutide lowered HbA1c by approximately 1.0-1.8% with accompanying weight loss, outperforming several active comparators including other GLP-1 agonists and insulin glargine on glycemic and weight endpoints. Hypoglycemia risk was low as a monotherapy because insulin secretion is glucose-dependent. These trials supported approval for type 2 diabetes.
Bottom line: Semaglutide produces large, reliable HbA1c reductions with weight loss in type 2 diabetes.
chronic weight management in obesity
Disease adjunctIn the phase-3 STEP 1 trial, adults without diabetes who received semaglutide 2.4 mg weekly with lifestyle intervention lost about 15% of body weight versus roughly 2.4% with placebo over 68 weeks, with nearly a third losing 20% or more. Companion STEP trials confirmed benefit across populations, including those with type 2 diabetes (with somewhat smaller loss). Weight is largely regained after discontinuation, underscoring chronic-disease management.
Bottom line: At the 2.4 mg dose, semaglutide produces clinically large, sustained weight loss as long as treatment continues.
cardiovascular event reduction
Disease adjunctThe SELECT trial randomized adults with established cardiovascular disease and overweight/obesity but without diabetes to semaglutide 2.4 mg or placebo and found about a 20% relative reduction in the composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. Earlier, the SUSTAIN-6 cardiovascular outcomes trial in type 2 diabetes showed reduced cardiovascular events. These outcome trials underpin the cardiovascular risk-reduction indication.
Bottom line: Semaglutide reduces major cardiovascular events in established cardiovascular disease, a benefit beyond glucose and weight.
How to take it
- Typical dose
- Prescriber-titrated: injectable started at 0.25 mg weekly and stepped up (to 1-2 mg for diabetes, up to 2.4 mg weekly for weight management); oral 3 mg then 7-14 mg daily
- Timing
- Injection once weekly on the same day; oral tablet on an empty stomach with <=120 mL water, then wait 30 minutes before food, drink, or other medicines
- With food
- Injectable independent of meals; oral Rybelsus strictly fasting as above for absorption
- How long to try
- Chronic therapy; weight tends to be regained after stopping, so the prescriber plans long-term use and reassessment
What to track
- HbA1c and fasting glucose (in diabetes)
- Body weight and waist circumference
- Signs of pancreatitis (severe persistent abdominal pain)
- Renal function during GI illness/dehydration
- Heart rate and any gallbladder symptoms
Safety
Common side effects
Nausea, vomiting, diarrhea, constipation (dose-related, usually transient), Abdominal pain and bloating, Decreased appetite, Injection-site reactions (injectable), Fatigue
Serious risks
- Boxed warning: thyroid C-cell tumors, including medullary thyroid carcinoma, seen in rodents (human relevance unknown)
- Acute pancreatitis
- Gallbladder disease (cholelithiasis, cholecystitis)
- Acute kidney injury from dehydration with severe GI symptoms
- Diabetic retinopathy worsening in some patients
- Severe hypoglycemia when combined with insulin or sulfonylureas
- Reports of ileus and aspiration risk under anesthesia from delayed gastric emptying
Who should avoid it
- People with a personal or family history of medullary thyroid carcinoma
- People with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- People with prior serious hypersensitivity to semaglutide
- People with a history of pancreatitis (use with caution)
- Pregnant individuals
Pregnancy & breastfeeding
Not recommended in pregnancy; discontinue at least 2 months before a planned pregnancy because of the long half-life.
Interactions
Additive glucose lowering raises hypoglycemia risk; doses of these often need reduction
Delayed gastric emptying can alter the rate/extent of absorption of co-administered oral drugs
Changed gastric emptying may affect absorption; monitor INR or drug levels
The strict fasting administration window for Rybelsus can conflict with levothyroxine timing and absorption
Choosing a product
Look for
- Only obtain via a licensed prescriber and pharmacy as FDA-approved Ozempic, Wegovy, or Rybelsus
- Supplied as a prefilled pen (injectable) or branded oral tablet with verified dose
- Dispensed with titration schedule and counseling on GI effects and storage
Be skeptical of
- Compounded 'semaglutide' from grey-market or med-spa sources with unverified salt forms or purity
- Research-only powders sold to be reconstituted for injection
- Any source marketing it for rapid weight loss without medical evaluation or titration
References by claim
type 2 diabetes glycemic control
chronic weight management in obesity
- Rubino et al., 2021 — PMC (2021) link
Track Semaglutide with Pilora
Set up dose reminders, check interactions, and join the community in the Pilora iPhone app.
Coming to App StoreDisclaimer: This page summarizes published clinical-trial data for educational purposes and is not medical advice or a recommendation to use this prescription medication. Dosing, eligibility, and monitoring must be decided by a licensed prescriber.